Next Generation Solutions
AAHI’s scientists apply a creative and pragmatic approach to protecting the world from disease. We develop and optimize our platform technologies to ensure that life-changing products can be made available to those who most need them.
Our immune-enhancing platforms provide the foundation for development and improvement of next-generation vaccine and immunotherapies that are not only potent, broad, and durable, but also practically and equitably accessible across diverse geographic, cultural, and economic regions.
We are enabling pandemic preparedness and rapid response.
Our adjuvant formulations and/or NLC can be made and stockpiled in readiness for combination with antigens or saRNA targeted to emerging threats.
We are eliminating cold chain requirements.
We have developed temperature stable products that can be transported and stored without the deep cold chain required by currently available mRNA vaccines.
We are working to protect against viral variants.
AAHI’s platform technologies can elicit broad and durable immune responses to protect against viral mutations.
AAHI’s formulation and RNA platforms are optimized to elicit a combination of T cells and antibodies as T cells may be more resilient and are critical to protection from viral variants and longer lasting immunity.
- AAHI’s RNA platform enables development of multivalent vaccines by loading NLC with saRNA constructs for multiple pathogens, by laoding NLC with multiple monovalent saRNA constructs, or by administering a combination of NLC loaded with different saRNA constructs.
We are expanding protection to vulnerable populations such as immunocompromised, elderly, and pediatric patients.
AAHI’s immune-stimulating platform technologies generate potent immune responses and help make vaccines effective for at-risk populations with waning or underdeveloped immune systems.
- AAHI’s immune-stimulating platform technologies generate potent immune responses, increasing efficacy in at-risk populations with waning or underdeveloped immune systems.
- AAHI’s 3M-052-SE adjuvant formulation formulated with a protein antigen is safe and shows broad protective efficacy against COVID in infant non-human primates
We are developing alternative routes of administration.
Our preclinical studies have shown that intranasal administration delivers strong mucosal immune responses, and may therefore provide enhanced protection from respiratory diseases and eliminate the need to administer certain vaccines by injection.
- AAHI’s dual TLR4 and TLR7/8 adjuvant formulation combined with a protein antigen is safe and immunogenic when administered intranasally and shows protective efficacy against COVID and Amebiasis.
- Based on our promising preclinical studies intranasally administering our COVID RNA vaccine candidate, BARDA is funding collaboration to develop an intranasally delivered RNA vaccine for pandemic influenza to establish proof-of-concept for inhalable RNA vaccines.
We are supporting local production and self-reliance.
Our immune-enhancing platforms use standard emulsion manufacturing technology and innovative and efficient manufacturing techniques that can be transferred to enable local production in low-and-middle income countries around the world.
- AAHI’s technology transfer and training in adjuvant manufacturing techniques enable self-reliance, even in low-resource areas, and fosters local production and expanded availability of vaccines and immunotherapies.
- Our NLC are produced with standard emulsification equipment and techniques to support global accessibility, including by eliminating the significant logistical difficulties that encumber production of Lipid Nanoparticles (LNPs) used with current RNA vaccines.
We are working toward environmental sustainability.
Our scientists are exploring ways in which we can reduce the burden on our ecosystems by sourcing environmentally sustainable raw materials and enabling more efficient use of scarce natural resources.
- Our platforms maximize the utility of raw materials, supporting production of more vaccine doses from limited materials. Our adjuvant formulations enable production of vaccines that use lower per-dose quantities of antigen, and our saRNA/NLC complex uses lower doses of RNA – in each case conserving raw materials and processing materials that are in short supply.
- We are working to develop sustainable synthetic and/or plant-based alternatives to squalene, a key vaccine adjuvant ingredient that is sourced from shark livers. We have also developed a purification method that more efficiently extracts QS21, a saponin adjuvant, from limited supplies of the bark of Quillaja Saponaria, an endangered Chilean soapbark tree.